Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 298 articles:
HTML format



Single Articles


    May 2020
  1. KAPADIA RK, Ney DE, Hannan M, Farley M, et al
    Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    J Neuroimmunol. 2020;344:577259.
    PubMed     Abstract available


    April 2020
  2. PREVEZIANOU A, Tzartos JS, Dagklis IE, Bentenidi E, et al
    Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
    J Neuroimmunol. 2020;344:577242.
    PubMed     Abstract available


  3. ANEJA J, Kuppili PP, Paul K, Panda S, et al
    Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male.
    J Neuroimmunol. 2020;343:577238.
    PubMed     Abstract available


  4. BOULLERNE AI, Adami GR, Schwartz JL, Skias D, et al
    Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.
    J Neuroimmunol. 2020;343:577237.
    PubMed     Abstract available


  5. PARKHOUSE RME, Carpio A, Cortez MM, von Kriegsheim A, et al
    Anti-brain protein autoantibodies are detectable in extraparenchymal but not parenchymal neurocysticercosis.
    J Neuroimmunol. 2020;344:577234.
    PubMed     Abstract available


    March 2020
  6. PRABHAT N, Chakravarty K, Pattnaik SN, Takkar A, et al
    Systemic lupus erythematosus with autoimmune neurological manifestations in a carrier of chronic granulomatous disease - a rare presentation.
    J Neuroimmunol. 2020;343:577229.
    PubMed     Abstract available


  7. MUKE I, Sprenger A, Bobylev I, Wiemer V, et al
    Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis.
    J Neuroimmunol. 2020;343:577218.
    PubMed     Abstract available


  8. MACCHI ZA, Kleinschmidt-DeMasters BK, Orjuela KD, Pastula DM, et al
    Glioblastoma as an autoimmune limbic encephalitis mimic: A case and review of the literature.
    J Neuroimmunol. 2020;342:577214.
    PubMed     Abstract available


  9. PETKOVIC F, Lazzarino GP, Engblom D, Blomqvist A, et al
    IL-6R expressed on CNS vascular endothelial cells contributes to the development of experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2020;342:577211.
    PubMed     Abstract available


  10. TAHMASEBIVAND M, Mousavi SR, Khorrami M, Ayromlou H, et al
    miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.
    J Neuroimmunol. 2020;342:577212.
    PubMed     Abstract available


  11. MCGILL MM, Sabikunnahar B, Fang Q, Teuscher C, et al
    The sex-specific role of p38 MAP kinase in CNS autoimmunity is regulated by estrogen receptor alpha.
    J Neuroimmunol. 2020;342:577209.
    PubMed    


    February 2020
  12. PEREZ CA, Shah EG, Butler IJ
    Mercury-induced autoimmunity: Report of two adolescent siblings with Morvan syndrome "plus" and review of the literature.
    J Neuroimmunol. 2020;342:577197.
    PubMed     Abstract available


  13. LISAK RP, Nedelkoska L, Benjamins JA
    Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis.
    J Neuroimmunol. 2020;342:577188.
    PubMed     Abstract available


  14. HABIB R, Ocklenburg S, Hoffjan S, Haghikia A, et al
    Association between shorter leukocyte telomeres and multiple sclerosis.
    J Neuroimmunol. 2020;341:577187.
    PubMed     Abstract available


  15. TRAN GT, Hodgkinson SJ, Carter N, Verma ND, et al
    Autoantigen specific IL-2 activated CD4(+)CD25(+)T regulatory cells inhibit induction of experimental autoimmune neuritis.
    J Neuroimmunol. 2020;341:577186.
    PubMed     Abstract available


    January 2020
  16. SHAHIDI SH, Kordi MR, Rajabi H, Malm C, et al
    Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis.
    J Neuroimmunol. 2020;341:577172.
    PubMed     Abstract available


  17. HEMING M, Lohmann L, Schulte-Mecklenbeck A, Brix T, et al
    Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
    J Neuroimmunol. 2020;341:577171.
    PubMed     Abstract available


  18. SAHAMI-FARD MH, Mozhdeh M, Izadpanah F, Kashani HH, et al
    Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis.
    J Neuroimmunol. 2020;341:577166.
    PubMed     Abstract available


  19. LIU S, Zhang X, Wang J, Yang H, et al
    Analysis of plasma autoantibodies for inflammatory cytokines in patients with first-episode schizophrenia among a Chinese population.
    J Neuroimmunol. 2020;341:577165.
    PubMed     Abstract available


  20. DAS NEVES SP, Santos G, Barros C, Pereira DR, et al
    Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms.
    J Neuroimmunol. 2020;340:577163.
    PubMed     Abstract available


  21. PANDYA D, Hellerslia V, Gettings E
    Acquired factor VIII inhibitor in a patient with multiple sclerosis treated with interferon beta-1a.
    J Neuroimmunol. 2020;340:577146.
    PubMed     Abstract available


  22. HAKANSSON I, Ernerudh J, Vrethem M, Dahle C, et al
    Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2020;340:577147.
    PubMed     Abstract available


    December 2019
  23. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Corrigendum to "Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis" [J Neuroimmunol. 2019 Dec 15;337:577070. doi: 10.1016/j.jneuroim.2019.577070. Epub 2019 Oct 24].
    J Neuroimmunol. 2019 Dec 27:577137. doi: 10.1016/j.jneuroim.2019.577137.
    PubMed    


  24. JOOB B, Wiwanitkit V
    Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barre Syndrome.
    J Neuroimmunol. 2019;339:577140.
    PubMed    


  25. LAZARIDIS K, Baltatzidou V, Tektonidis N, Tzartos SJ, et al
    Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2019;339:577136.
    PubMed     Abstract available


  26. SHIMASAKI C, Frye RE, Trifiletti R, Cooperstock M, et al
    Evaluation of the Cunningham Panel in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes
    J Neuroimmunol. 2019;339:577138.
    PubMed     Abstract available


  27. UZAWA A, Ozawa Y, Yasuda M, Oda F, et al
    Increased serum acetylcholine receptor alpha1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis.
    J Neuroimmunol. 2019;339:577125.
    PubMed     Abstract available


  28. PEREZ CA, Agyei P, Gogia B, Harrison R, et al
    Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease.
    J Neuroimmunol. 2019;339:577124.
    PubMed     Abstract available


  29. CAVALLA P, Caropreso P, Limoncelli S, Bosa C, et al
    Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders.
    J Neuroimmunol. 2019;339:577122.
    PubMed     Abstract available


    November 2019
  30. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    J Neuroimmunol. 2019;339:577113.
    PubMed     Abstract available


  31. MARCUCCI SB, Obeidat AZ
    EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis.
    J Neuroimmunol. 2019;339:577116.
    PubMed     Abstract available


  32. GLENN JD, Pantoja IM, Caturegli P, Whartenby KA, et al
    MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;339:577115.
    PubMed     Abstract available


  33. AMMITZBOLL C, von Essen MR, Chow HH, McWilliam O, et al
    MAIT cell subtypes in multiple sclerosis.
    J Neuroimmunol. 2019;339:577117.
    PubMed     Abstract available


  34. SPANIER JA, Nashold FE, Nelson CD, Praska CE, et al
    Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4(+) T cell CTLA-4 expression.
    J Neuroimmunol. 2019;338:577105.
    PubMed     Abstract available


  35. NASI M, Bianchini E, De Biasi S, Gibellini L, et al
    Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2019;338:577107.
    PubMed     Abstract available


  36. GAETANI L, Di Carlo M, Brachelente G, Valletta F, et al
    Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis.
    J Neuroimmunol. 2019;339:577108.
    PubMed     Abstract available


  37. ARRU G, Sechi E, Mariotto S, Zarbo IR, et al
    Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    J Neuroimmunol. 2019;338:577110.
    PubMed     Abstract available


    October 2019
  38. CAO Q, Zheng C, Xie Z, Liu L, et al
    The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3.
    J Neuroimmunol. 2019;338:577079.
    PubMed     Abstract available


  39. KOLIC I, Stojkovic L, Dincic E, Jovanovic I, et al
    Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;338:577090.
    PubMed     Abstract available


  40. NOVIKOVA NS, Diatlova AS, Derevtsova KZ, Korneva EA, et al
    Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;337:577070.
    PubMed     Abstract available


  41. HAN J, Zhang J, Li M, Zhang Y, et al
    A novel MuSK cell-based myasthenia gravis diagnostic assay.
    J Neuroimmunol. 2019;337:577076.
    PubMed     Abstract available


  42. BASNYAT P, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.
    J Neuroimmunol. 2019;335:577020.
    PubMed     Abstract available


  43. SOUTO EB, Lima B, Campos JR, Martins-Gomes C, et al
    Myasthenia gravis: State of the art and new therapeutic strategies.
    J Neuroimmunol. 2019;337:577080.
    PubMed     Abstract available


  44. KAMMEYER R, Piquet AL
    Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature.
    J Neuroimmunol. 2019;337:577084.
    PubMed     Abstract available


  45. PETERSEN ER, Ammitzboll C, Sondergaard HB, Oturai AB, et al
    Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis.
    J Neuroimmunol. 2019;337:577085.
    PubMed     Abstract available


    September 2019
  46. RANJBAR R, Karampoor S, Jalilian FA
    The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.
    J Neuroimmunol. 2019;337:577069.
    PubMed     Abstract available


  47. BOYAO Y, Mengjiao S, Caicai B, Xiaoling L, et al
    Dynamic expression of autophagy-related factors in autoimmune encephalomyelitis and exploration of curcumin therapy.
    J Neuroimmunol. 2019;337:577067.
    PubMed     Abstract available


  48. KURTUNCU M, Yilmaz V, Akcay HI, Turkoglu R, et al
    Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2019;337:577065.
    PubMed     Abstract available


  49. CARLOS CE, Gianfranco CS, Miguel CC, Crist EA, et al
    Is there a significant association between tumor necrosis factor alpha -863C/A polymorphism and the development of Guillain-Barre Syndrome?
    J Neuroimmunol. 2019;337:577064.
    PubMed    


  50. ABDEL-DAYEM MA, Shaker ME, Gameil NM
    Impact of interferon beta-1b, interferon beta-1a and fingolimod therapies on serum interleukins-22, 32alpha and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577062.
    PubMed     Abstract available


  51. AFSHAR B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, et al
    The role of immune regulatory molecules in multiple sclerosis.
    J Neuroimmunol. 2019;337:577061.
    PubMed     Abstract available


  52. MARGONI M, Carotenuto A
    Very late-onset recurrent myelitis in a patient diagnosed with antiphospholipid syndrome: A puzzle of autoimmunity.
    J Neuroimmunol. 2019;337:577051.
    PubMed     Abstract available


  53. BROOKS PT, Bell JA, Bejcek CE, Malik A, et al
    An antibiotic depleted microbiome drives severe Campylobacter jejuni-mediated Type 1/17 colitis, Type 2 autoimmunity and neurologic sequelae in a mouse model.
    J Neuroimmunol. 2019;337:577048.
    PubMed     Abstract available


    August 2019
  54. LIANG H, Gao W, Liu X, Liu J, et al
    The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population.
    J Neuroimmunol. 2019;337:577045.
    PubMed     Abstract available


  55. ZAROBKIEWICZ MK, Kowalska W, Halczuk P, Wos J, et al
    RORgammaT is overexpressed in iNKT and gammadelta T cells during relapse in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577046.
    PubMed     Abstract available


  56. ZHANG G, Wang Q, Song Y, Cheng P, et al
    Intravenous immunoglobulin promotes the proliferation of CD4(+)CD25(+) Foxp3(+) regulatory T cells and the cytokines secretion in patients with Guillain-Barre syndrome in vitro.
    J Neuroimmunol. 2019;336:577042.
    PubMed     Abstract available


  57. SVEINSSON O, Piehl F, Aspegren O, Hietala MA, et al
    Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome.
    J Neuroimmunol. 2019;336:577028.
    PubMed     Abstract available


  58. DURCAN R, Heffron C, Sweeney B
    Natalizumab induced cutaneous sarcoidosis-like reaction.
    J Neuroimmunol. 2019;333:476955.
    PubMed     Abstract available


  59. KAUSHANSKY N, Kaminitz A, Allouche-Arnon H, Ben-Nun A, et al
    Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c(+)CD11b(+)Gr1(+) myeloid-derived dendritic cells.
    J Neuroimmunol. 2019;333:476953.
    PubMed     Abstract available


    July 2019
  60. NAKAMURA Y, Igaki K, Uga K, Shibata A, et al
    Pharmacological evaluation of TAK-828F, a novel orally available RORgammat inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2019;335:577016.
    PubMed     Abstract available


  61. NOSADINI M, Toldo I, Tascini B, Bien CG, et al
    LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
    J Neuroimmunol. 2019;335:577008.
    PubMed     Abstract available


  62. DEL FABBRO L, de Gomes MG, Souza LC, Goes AR, et al
    Chrysin suppress immune responses and protects from experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2019;335:577007.
    PubMed     Abstract available


  63. NICOLETTI F, Mazzon E, Fagone P, Mangano K, et al
    Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF.
    J Neuroimmunol. 2019;332:224-232.
    PubMed     Abstract available


  64. DZANGUE-TCHOUPOU G, Allenbach Y, Preusse C, Stenzel W, et al
    Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.
    J Neuroimmunol. 2019;332:212-215.
    PubMed     Abstract available


  65. JAZEBI N, Rodrigo S, Gogia B, Shawagfeh A, et al
    Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
    J Neuroimmunol. 2019;332:135-137.
    PubMed     Abstract available


  66. ENRIQUEZ CAG, Espiritu AI, Pasco PMD
    Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
    J Neuroimmunol. 2019;332:126-134.
    PubMed     Abstract available


  67. NEEDHAM EJ, Helmy A, Zanier ER, Jones JL, et al
    The immunological response to traumatic brain injury.
    J Neuroimmunol. 2019;332:112-125.
    PubMed     Abstract available


  68. FREUND B, Ritzl EK
    A review of EEG in anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2019;332:64-68.
    PubMed     Abstract available


  69. CAVALIERE E, Nosadini M, Pelizza MF, Ventura G, et al
    Anti-NMDAR encephalitis preceded by non-herpetic central nervous system infection: Systematic literature review and first case of tick-borne encephalitis triggering anti-NMDAR encephalitis.
    J Neuroimmunol. 2019;332:1-7.
    PubMed     Abstract available


    June 2019
  70. KIMURA A, Takemura M, Yamamoto Y, Hayashi Y, et al
    Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications.
    J Neuroimmunol. 2019;334:576999.
    PubMed     Abstract available


  71. NICKEL M, Eid F, Jukkola P, Gu C, et al
    Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit.
    J Neuroimmunol. 2019;334:576998.
    PubMed     Abstract available


  72. LAMPORT AC, Chedrawe M, Nichols M, Robertson GS, et al
    Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum.
    J Neuroimmunol. 2019;334:576995.
    PubMed     Abstract available


  73. IMITOLA J
    Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair.
    J Neuroimmunol. 2019;331:1-3.
    PubMed    


  74. ANTEL JP, Lin YH, Cui QL, Pernin F, et al
    Immunology of oligodendrocyte precursor cells in vivo and in vitro.
    J Neuroimmunol. 2019;331:28-35.
    PubMed     Abstract available


  75. ZORLU N, Hoffjan S, Haghikia A, Deyneko IV, et al
    Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis.
    J Neuroimmunol. 2019;334:576979.
    PubMed     Abstract available


    May 2019
  76. KOCH MW, Liu WQ, Camara-Lemarroy C, Zhang Y, et al
    Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
    J Neuroimmunol. 2019;334:576974.
    PubMed     Abstract available


  77. ZURAWSKA A, Mycko MP, Selmaj KW
    Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis.
    J Neuroimmunol. 2019;334:576971.
    PubMed     Abstract available


  78. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Abstract available


  79. TOMESCU-BACIU A, Johansen JN, Holmoy T, Greiff V, et al
    Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis.
    J Neuroimmunol. 2019;333:576966.
    PubMed     Abstract available


  80. SHOU J, Peng J, Zhao Z, Huang X, et al
    CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;333:576967.
    PubMed     Abstract available


  81. XU H, Zhang M, Li XL, Li H, et al
    Corrigendum to: "low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways" [Journal of Neuroimmunology 281 (2015) 61-67].
    J Neuroimmunol. 2019;330:181-183.
    PubMed    


  82. QU Z, Zheng N, Wei Y, Chen Y, et al
    Effect of cornel iridoid glycoside on microglia activation through suppression of the JAK/STAT signalling pathway.
    J Neuroimmunol. 2019;330:96-107.
    PubMed     Abstract available


  83. SHOUMAN K, Prieto PG, Stino AM, Lisak RP, et al
    Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder.
    J Neuroimmunol. 2019;330:87-89.
    PubMed     Abstract available


  84. DENG B, Yu H, Liu X, Yu X, et al
    Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients.
    J Neuroimmunol. 2019;330:81-86.
    PubMed     Abstract available


  85. KELLER CW, Quast I, Dalakas MC, Lunemann JD, et al
    IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.
    J Neuroimmunol. 2019;330:23-27.
    PubMed     Abstract available


  86. KAMO H, Ueno Y, Sugiyama M, Miyamoto N, et al
    Pontine hemorrhage accompanied by neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2019;330:19-22.
    PubMed     Abstract available


  87. MONTEIRO C, Fernandes G, Kasahara TM, Barros PO, et al
    The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2019;330:12-18.
    PubMed     Abstract available


  88. SPENCE S, Ng D, Casault C
    Atypical presentation of fulminant primary central nervous system angiitis.
    J Neuroimmunol. 2019;330:1-4.
    PubMed     Abstract available


  89. BRIANI C, Salvalaggio A, Ruiz M, Cacciavillani M, et al
    Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy.
    J Neuroimmunol. 2019;330:178-180.
    PubMed     Abstract available


  90. YOON L, Kim BR, Kim HY, Kwak MJ, et al
    Clinical characterization of anti-GQ1b antibody syndrome in Korean children.
    J Neuroimmunol. 2019;330:170-173.
    PubMed     Abstract available


  91. JING S, Lu J, Song J, Luo S, et al
    Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.
    J Neuroimmunol. 2019;332:216-223.
    PubMed     Abstract available


  92. LOVETT-RACKE AE, Gormley M, Liu Y, Yang Y, et al
    B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    J Neuroimmunol. 2019;332:187-197.
    PubMed     Abstract available


  93. BORHANI-HAGHIGHI M, Mohamadi Y
    The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2019;333:476958.
    PubMed     Abstract available


    April 2019
  94. SETIADI AF, Abbas AR, Jeet S, Wong K, et al
    IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;332:147-154.
    PubMed     Abstract available


  95. KIRA JI, Isobe N
    Helicobacter pylori infection and demyelinating disease of the central nervous system.
    J Neuroimmunol. 2019;329:14-19.
    PubMed     Abstract available


  96. KIMURA A, Takekoshi A, Yoshikura N, Hayashi Y, et al
    Clinical characteristics of autoimmune GFAP astrocytopathy.
    J Neuroimmunol. 2019;332:91-98.
    PubMed     Abstract available


  97. MADDISON P, Sadalage G, Ambrose PA, Jacob S, et al
    False-positive acetylcholine receptor antibody results in patients without myasthenia gravis.
    J Neuroimmunol. 2019;332:69-72.
    PubMed     Abstract available


  98. SUN Y, Jing Y, Huang M, Ma J, et al
    The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides.
    J Neuroimmunol. 2019;332:78-90.
    PubMed     Abstract available


    March 2019
  99. SCHLIFFKE S, Carambia A, Akyuz N, Thiele B, et al
    T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model.
    J Neuroimmunol. 2019;332:49-56.
    PubMed     Abstract available


  100. VAITAITIS GM, Yussman MG, Wagner DH Jr
    A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;332:8-15.
    PubMed     Abstract available


  101. ROJC B, Podnar B, Graus F
    A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: Different biological evolution of the two associated antibodies.
    J Neuroimmunol. 2019;328:86-88.
    PubMed     Abstract available


  102. GARG M, Mittal J, Gupta P
    Association of typhoid fever with anti-NMDAR encephalitis in a young child.
    J Neuroimmunol. 2019;328:76-77.
    PubMed    


  103. GASTALDI M, Arbasino C, Dallocchio C, Diamanti L, et al
    NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease.
    J Neuroimmunol. 2019;328:35-37.
    PubMed     Abstract available


  104. VOO VTF, O'Brien T, Butzkueven H, Monif M, et al
    The role of vitamin D and P2X7R in multiple sclerosis.
    J Neuroimmunol. 2019;330:159-169.
    PubMed     Abstract available


  105. HILLIS JM, Mateen FJ
    Neuromyelitis optica after splenectomy: A secondary autoimmune phenomenon.
    J Neuroimmunol. 2019;330:152-154.
    PubMed     Abstract available


  106. CIERNY D, Michalik J, Dubovan P, Skerenova M, et al
    The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks.
    J Neuroimmunol. 2019;330:123-129.
    PubMed     Abstract available


  107. ANNUNZIATA P, Masi G, Cioni C
    Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.
    J Neuroimmunol. 2019;330:130-135.
    PubMed     Abstract available


  108. AMMITZBOLL C, Bornsen L, Petersen ER, Oturai AB, et al
    Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.
    J Neuroimmunol. 2019;330:90-95.
    PubMed     Abstract available


    February 2019
  109. ZHANG DQ, Deng Y, Zhang LJ, Li LM, et al
    Elevated resistin levels may regulate high mobility group box 1 expression in Guillain-Barre syndrome.
    J Neuroimmunol. 2019;330:59-66.
    PubMed     Abstract available


  110. DA SILVA BERNARDES M, Antao Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, et al
    Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease?
    J Neuroimmunol. 2019;330:74-80.
    PubMed     Abstract available


  111. ZAROBKIEWICZ MK, Kowalska W, Rolinski J, Bojarska-Junak AA, et al
    gammadelta T lymphocytes in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;330:67-73.
    PubMed     Abstract available


  112. AL-TEMAIMI R, Cherian P, Abu-Farha M, Alroughani R, et al
    Angiopoietin-like proteins in multiple sclerosis.
    J Neuroimmunol. 2019;330:31-34.
    PubMed     Abstract available


  113. GILLINDER L, Papacostas J, Dionisio S
    Electroclinical insights into autoimmune epilepsy.
    J Neuroimmunol. 2019;330:44-47.
    PubMed     Abstract available


  114. SAVAGE SA, Irani SR, Leite MI, Zeman AZ, et al
    NMDA receptor antibody encephalitis presenting as Transient Epileptic Amnesia.
    J Neuroimmunol. 2019;327:41-43.
    PubMed     Abstract available


    January 2019
  115. COSSU D, Yokoyama K, Sakanishi T, Momotani E, et al
    Adjuvant and antigenic properties of Mycobacterium avium subsp. paratuberculosis on experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019 Jan 23. pii: S0165-5728(18)30552.
    PubMed     Abstract available


  116. JAYASIMHAN A, Ellis DP, Ziegler AI, Slattery RM, et al
    Pancreatic ductal cell antigens are important in the development of invasive insulitis in Non-Obese Diabetic mice.
    J Neuroimmunol. 2019 Jan 18. pii: S0165-5728(18)30263.
    PubMed     Abstract available


  117. MAUSNER-FAINBERG K, Penn M, Golan M, Benhamou M, et al
    Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30476.
    PubMed     Abstract available


  118. DOLATI S, Babaloo Z, Ayromlou H, Ahmadi M, et al
    Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30466.
    PubMed     Abstract available


  119. KOHLER S, Keil T, Alexander T, Thiel A, et al
    Altered naive CD4(+) T cell homeostasis in myasthenia gravis and thymoma patients.
    J Neuroimmunol. 2019 Jan 11. pii: S0165-5728(18)30380.
    PubMed     Abstract available


    December 2018
  120. EMAMI ALEAGHA MS, Siroos B, Allameh A, Shakiba S, et al
    Calcitriol, but not FGF23, increases in CSF and serum of MS patients.
    J Neuroimmunol. 2018;328:89-93.
    PubMed     Abstract available


  121. DEMIR S, Pitarokoili K, Linker R, Gold R, et al
    Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
    J Neuroimmunol. 2018;328:78-85.
    PubMed     Abstract available


  122. ARAMIDEH KHOUY R, Karampoor S, Keyvani H, Bokharaei-Salim F, et al
    The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    J Neuroimmunol. 2018;328:94-97.
    PubMed     Abstract available


  123. XIE Y, Li Z, Wang Y, Xue X, et al
    Effects of moderate- versus high- intensity swimming training on inflammatory and CD4(+) T cell subset profiles in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2018;328:60-67.
    PubMed     Abstract available


  124. MEHTA D, Wani S, Wallace L, Henders AK, et al
    Cumulative influence of parity-related genomic changes in multiple sclerosis.
    J Neuroimmunol. 2018;328:38-49.
    PubMed     Abstract available


  125. YOUSEFI F, Lavi Arab F, Saeidi K, Amiri H, et al
    Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection.
    J Neuroimmunol. 2018;328:20-34.
    PubMed     Abstract available


    November 2018
  126. LEE EJ, Lim YM, Kim SY, Lee J, et al
    The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2018;328:1-4.
    PubMed     Abstract available


  127. MASOUMI F, Ghorbani S, Talebi F, Branton WG, et al
    Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;328:50-59.
    PubMed     Abstract available


  128. MONTEIRO A, Cruto C, Rosado P, Rosado L, et al
    Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    J Neuroimmunol. 2018;326:49-54.
    PubMed     Abstract available


  129. ANNIBALI V, Umeton R, Palermo A, Severa M, et al
    Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients.
    J Neuroimmunol. 2018;324:165-171.
    PubMed     Abstract available


  130. LOTAN I, Hellmann MA, Benninger F, Stiebel-Kalish H, et al
    Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    J Neuroimmunol. 2018;324:115-118.
    PubMed     Abstract available


  131. MOORE JR, Hubler SL, Nelson CD, Nashold FE, et al
    1,25-Dihydroxyvitamin D3 increases the methionine cycle, CD4(+) T cell DNA methylation and Helios(+)Foxp3(+) T regulatory cells to reverse autoimmune neurodegenerative disease.
    J Neuroimmunol. 2018;324:100-114.
    PubMed     Abstract available


  132. ROCHA NP, Colpo GD, Bravo-Alegria J, Lincoln JA, et al
    Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis.
    J Neuroimmunol. 2018;326:45-48.
    PubMed     Abstract available


  133. WANG SX, Yang CL, Zhang M, Zhang P, et al
    Sulfatides ameliorate experimental autoimmune neuritis by suppressing Th1/Th17 cells.
    J Neuroimmunol. 2018;326:55-61.
    PubMed     Abstract available


  134. BOUXIN M, Schvartz B, Mestrallet S, Debrumetz A, et al
    Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review.
    J Neuroimmunol. 2018;326:28-32.
    PubMed     Abstract available


  135. JENSEN PEH, Warnke C, Ingenhoven K, Piccoli L, et al
    Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
    J Neuroimmunol. 2018;326:19-27.
    PubMed     Abstract available


    October 2018
  136. RAMIREZ GA, Coletto LA, Bozzolo EP, Citterio L, et al
    The TRPC6 intronic polymorphism, associated with the risk of neurological disorders in systemic lupus erythematous, influences immune cell function.
    J Neuroimmunol. 2018;325:43-53.
    PubMed     Abstract available


  137. CAVAZZANA I, Alberici A, Bonomi E, Ottaviani R, et al
    Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?
    J Neuroimmunol. 2018;325:61-63.
    PubMed     Abstract available


  138. SAFIZADEH B, Hoshyar R, Mehrpour M, Eftekhar M, et al
    The role of expression and activity of 15-Lipoxygenase isoforms and related cytokines in patients with Multiple Sclerosis and healthy controls.
    J Neuroimmunol. 2018;325:32-42.
    PubMed     Abstract available


  139. ROSSETTI I, Zambusi L, Finardi A, Bodini A, et al
    Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:94-104.
    PubMed     Abstract available


  140. KVISTAD SS, Myhr KM, Holmoy T, Benth JS, et al
    Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.
    J Neuroimmunol. 2018;323:73-77.
    PubMed     Abstract available


  141. DUBEY D, Kothapalli N, McKeon A, Flanagan EP, et al
    Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction.
    J Neuroimmunol. 2018;323:62-72.
    PubMed     Abstract available


  142. DUBEY D, Hussain RZ, Miller-Little WA, Salter A, et al
    PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.
    J Neuroimmunol. 2018;323:53-55.
    PubMed     Abstract available


  143. SLAVIN YN, Bo M, Caggiu E, Sechi G, et al
    High levels of antibodies against PtpA and PknG secreted by Mycobacterium avium ssp. paratuberculosis are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients.
    J Neuroimmunol. 2018;323:49-52.
    PubMed     Abstract available


  144. AMORUSO A, Blonda M, D'Arrigo G, Grasso R, et al
    Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients.
    J Neuroimmunol. 2018;323:43-48.
    PubMed     Abstract available


  145. HOCAOGLU M, Durmus H, Ozkan B, Yentur SP, et al
    Increased costimulatory molecule expression of thymic and peripheral B cells and a sensitivity to IL-21 in myasthenia gravis.
    J Neuroimmunol. 2018;323:36-42.
    PubMed     Abstract available


  146. HAARMANN A, Hahnel L, Schuhmann MK, Buttmann M, et al
    Age-adjusted CSF beta2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
    J Neuroimmunol. 2018;323:19-27.
    PubMed     Abstract available


  147. SHAKERIAN L, Ghorbani S, Talebi F, Noorbakhsh F, et al
    MicroRNA-150 targets PU.1 and regulates macrophage differentiation and function in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;323:167-174.
    PubMed     Abstract available


  148. DEBNATH M, Nagappa M, Subbanna M, Sundaravadivel P, et al
    Th17 pathway signatures in a large Indian cohort of Guillain Barre syndrome.
    J Neuroimmunol. 2018;323:125-130.
    PubMed     Abstract available


  149. BLUM S, Ji Y, Pennisi D, Li Z, et al
    Genome-wide association study in Guillain-Barre syndrome.
    J Neuroimmunol. 2018;323:109-114.
    PubMed     Abstract available


  150. MOHAMMADZADEH A, Rad IA, Ahmadi-Salmasi B
    CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
    J Neuroimmunol. 2018;323:105-108.
    PubMed     Abstract available


  151. KOSTIC M, Zivkovic N, Cvetanovic A, Stojanovic I, et al
    Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.
    J Neuroimmunol. 2018;323:1-9.
    PubMed     Abstract available


  152. AQEL SI, Granitto MC, Nuro-Gyina PK, Pei W, et al
    Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;325:20-28.
    PubMed     Abstract available


  153. ALROUJI M, Manouchehrinia A, Gran B, Constantinescu CS, et al
    Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis.
    J Neuroimmunol. 2018 Oct 9. pii: S0165-5728(18)30130.
    PubMed     Abstract available


  154. SABRE L, Guptill JT, Russo M, Juel VC, et al
    Circulating microRNA plasma profile in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2018 Oct 6. pii: S0165-5728(18)30383.
    PubMed     Abstract available


  155. TAVAKOLPOUR V, Shokri G, Naser Moghadasi A, Mozafari Nahavandi P, et al
    Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.
    J Neuroimmunol. 2018 Oct 4. pii: S0165-5728(18)30173.
    PubMed     Abstract available


  156. SUGIMOTO K, Hiwasa T, Shibuya K, Hirano S, et al
    Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
    J Neuroimmunol. 2018;325:54-60.
    PubMed     Abstract available


    September 2018
  157. IWASA K, Yoshikawa H, Furukawa Y, Yamada M, et al
    Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis.
    J Neuroimmunol. 2018 Sep 27. pii: S0165-5728(18)30353.
    PubMed     Abstract available


  158. CASTOLDI V, Marenna S, Santangelo R, d'Isa R, et al
    Optic nerve involvement in experimental autoimmune encephalomyelitis to homologous spinal cord homogenate immunization in the dark agouti rat.
    J Neuroimmunol. 2018;325:1-9.
    PubMed     Abstract available


  159. JAFARZADEH A, Nemati M
    Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    J Neuroimmunol. 2018;324:54-75.
    PubMed     Abstract available


  160. MCWILLIAM O, Sellebjerg F, Marquart HV, von Essen MR, et al
    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTalpha and TGFbeta1 response.
    J Neuroimmunol. 2018 Sep 7. pii: S0165-5728(18)30276.
    PubMed     Abstract available


    August 2018
  161. SALAPA HE, Johnson C, Hutchinson C, Popescu BF, et al
    Dysfunctional RNA binding proteins and stress granules in multiple sclerosis.
    J Neuroimmunol. 2018 Aug 29. pii: S0165-5728(18)30377.
    PubMed     Abstract available


  162. FENOGLIO C, Oldoni E, Serpente M, De Riz MA, et al
    LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients.
    J Neuroimmunol. 2018 Aug 27. pii: S0165-5728(18)30259.
    PubMed     Abstract available


  163. HOU H, Cao R, Quan M, Sun Y, et al
    Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
    J Neuroimmunol. 2018;324:26-34.
    PubMed     Abstract available


  164. MORIGUCHI K, Miyamoto K, Fukumoto Y, Kusunoki S, et al
    4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice.
    J Neuroimmunol. 2018;323:131-135.
    PubMed     Abstract available


  165. CHEDRAWE MAJ, Holman SP, Lamport AC, Akay T, et al
    Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
    J Neuroimmunol. 2018;321:72-82.
    PubMed     Abstract available


  166. FEKI S, Gargouri S, Mejdoub S, Dammak M, et al
    The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis.
    J Neuroimmunol. 2018;321:66-71.
    PubMed     Abstract available


  167. FAGONE P, Mazzon E, Chikovani T, Saraceno A, et al
    Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis.
    J Neuroimmunol. 2018;321:41-48.
    PubMed     Abstract available


  168. LAI W, Kinoshita M, Peng A, Li W, et al
    Does pregnancy affect women with multiple sclerosis? A prospective study in Western China.
    J Neuroimmunol. 2018;321:24-28.
    PubMed     Abstract available


  169. MOHAJER B, Abbasi N, Pishgar F, Abdolalizadeh A, et al
    HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis.
    J Neuroimmunol. 2018;321:117-124.
    PubMed     Abstract available


    July 2018
  170. MIYAKE S, Yamamura T
    Gut environmental factors and multiple sclerosis.
    J Neuroimmunol. 2018 Jul 27. pii: S0165-5728(17)30414.
    PubMed     Abstract available


  171. NAKAMURA R, Makino T, Hanada T, Terakawa M, et al
    Heterogeneity of auto-antibodies against nAChR in myasthenic serum and their pathogenic roles in experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2018;320:64-75.
    PubMed     Abstract available


  172. KARAMPOOR S, Zahednasab H, Etemadifar M, Keyvani H, et al
    The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
    J Neuroimmunol. 2018;320:11-14.
    PubMed     Abstract available


    June 2018
  173. HAASE S, Wilck N, Kleinewietfeld M, Muller DN, et al
    Sodium chloride triggers Th17 mediated autoimmunity.
    J Neuroimmunol. 2018 Jun 30. pii: S0165-5728(17)30512.
    PubMed     Abstract available


  174. SABERI R, Sharif M, Sarvi S, Aghayan SA, et al
    Is Toxoplasma gondii playing a positive role in multiple sclerosis risk? A systematic review and meta-analysis.
    J Neuroimmunol. 2018 Jun 22. pii: S0165-5728(17)30579.
    PubMed     Abstract available


  175. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.
    PubMed    


  176. SERIZAWA K, Tomizawa-Shinohara H, Magi M, Yogo K, et al
    Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:71-79.
    PubMed     Abstract available


  177. TIJERO B, Del Pino R, Perez-Concha T, Acera MA, et al
    Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy.
    J Neuroimmunol. 2018;319:68-70.
    PubMed     Abstract available


  178. YOSHIKURA N, Kimura A, Fukata M, Fukata Y, et al
    Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
    J Neuroimmunol. 2018;319:63-67.
    PubMed     Abstract available


  179. HIRATSUKA D, Furube E, Taguchi K, Tanaka M, et al
    Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;319:41-54.
    PubMed     Abstract available


  180. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Abstract available


  181. FAGONE P, Mazzon E, Cavalli E, Bramanti A, et al
    Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences.
    J Neuroimmunol. 2018 Jun 15. pii: S0165-5728(18)30141.
    PubMed     Abstract available


    May 2018
  182. DUPREE JL, Feinstein DL
    Influence of diet on axonal damage in the EAE mouse model of multiple sclerosis.
    J Neuroimmunol. 2018 May 20. pii: S0165-5728(18)30104.
    PubMed     Abstract available


  183. BREUER J, Loser K, Mykicki N, Wiendl H, et al
    Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?
    J Neuroimmunol. 2018 May 18. pii: S0165-5728(17)30478.
    PubMed     Abstract available


  184. CHU F, Shi M, Zheng C, Shen D, et al
    The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;318:1-7.
    PubMed     Abstract available


  185. SABRE L, Maddison P, Sadalage G, Ambrose PA, et al
    Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
    J Neuroimmunol. 2018 May 8. pii: S0165-5728(18)30122.
    PubMed     Abstract available


    April 2018
  186. DUBEY D, Hinson SR, Jolliffe EA, Zekeridou A, et al
    Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1year.
    J Neuroimmunol. 2018 Apr 27. pii: S0165-5728(18)30160.
    PubMed     Abstract available


  187. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Abstract available


  188. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Abstract available


  189. LI J, Qiu D, Chen Z, Du W, et al
    miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells.
    J Neuroimmunol. 2018 Apr 4. pii: S0165-5728(18)30166.
    PubMed     Abstract available


    March 2018
  190. ZAGORITI Z, Lagoumintzis G, Perroni G, Papathanasiou G, et al
    Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?
    J Neuroimmunol. 2018 Mar 17. pii: S0165-5728(17)30559.
    PubMed     Abstract available


  191. ALLENDER E, Deol H, Schram S, Maheras KJ, et al
    Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2018 Mar 10. pii: S0165-5728(17)30466.
    PubMed     Abstract available


  192. PAUNOVIC V, Petrovic IV, Milenkovic M, Janjetovic K, et al
    Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients.
    J Neuroimmunol. 2018 Mar 5. pii: S0165-5728(17)30538.
    PubMed     Abstract available


  193. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Abstract available


  194. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Abstract available


    February 2018
  195. MONTEIRO A, Cruto C, Rosado P, Martinho A, et al
    Characterization of circulating gamma-delta T cells in relapsing vs remission multiple sclerosis.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30533.
    PubMed     Abstract available


  196. BARBOUR M, Wood R, Hridi SU, Wilson C, et al
    The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30457.
    PubMed     Abstract available


  197. ROZMILOWSKA IM, Adamczyk-Sowa MH
    What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?
    J Neuroimmunol. 2018;315:50-57.
    PubMed    


  198. KUHN I, Rogosch T, Schindler TI, Tackenberg B, et al
    Serum titers of autoantibodies against alpha-synuclein and tau in child- and adulthood.
    J Neuroimmunol. 2018;315:33-39.
    PubMed     Abstract available


  199. GEORGE JD, Kim E, Spain R, Bourdette D, et al
    Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2018;315:24-27.
    PubMed     Abstract available


  200. IP PP, Chung CY, Chang CC, Lee YF, et al
    Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
    J Neuroimmunol. 2018 Feb 8. pii: S0165-5728(17)30498.
    PubMed     Abstract available


    January 2018
  201. LIU C, Liu H, Jin H, Yue X, et al
    Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.
    J Neuroimmunol. 2018 Jan 31. pii: S0165-5728(17)30560.
    PubMed     Abstract available


  202. HOR JY, Lim TT, Cheng MC, Chia YK, et al
    Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy.
    J Neuroimmunol. 2018 Jan 30. pii: S0165-5728(17)30491.
    PubMed     Abstract available


  203. RAHMAN MI, Jahan I, Khalid MM, Jahan I, et al
    CD1A and CD1E gene polymorphisms are not associated with susceptibility to Guillain-Barre syndrome in the Bangladeshi population.
    J Neuroimmunol. 2018;314:8-12.
    PubMed     Abstract available


  204. MEYER SAUTEUR PM, Huizinga R, Tio-Gillen AP, Drenthen J, et al
    Intrathecal antibody responses to GalC in Guillain-Barre syndrome triggered by Mycoplasma pneumoniae.
    J Neuroimmunol. 2018;314:13-16.
    PubMed     Abstract available


  205. LOSHAJ-SHALA A, Colzani M, Brezovska K, Poceva Panovska A, et al
    Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barre syndrome.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30422.
    PubMed     Abstract available


  206. VOGRIG A, Pauletto G, Belgrado E, Pegolo E, et al
    Effect of thymectomy on refractory autoimmune status epilepticus.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(17)30485.
    PubMed     Abstract available


  207. LV J, Li L, Li W, Ji K, et al
    Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis.
    J Neuroimmunol. 2018 Jan 9. pii: S0165-5728(18)30015.
    PubMed     Abstract available


  208. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Abstract available


  209. MASUDA H, Mori M, Umehara K, Furihata T, et al
    Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30562.
    PubMed     Abstract available


  210. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Abstract available


    December 2017
  211. DETRICK B, Gangaputra S, Palsgrove DN, Heaney CD, et al
    Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients.
    J Neuroimmunol. 2017 Dec 29. pii: S0165-5728(17)30269.
    PubMed     Abstract available


  212. IMITOLA J, Rasouli J, Watanabe F, Mahajan K, et al
    Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.
    J Neuroimmunol. 2017 Dec 22. pii: S0165-5728(17)30304.
    PubMed     Abstract available


  213. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Abstract available


  214. BHAT R, Mahapatra S, Axtell RC, Steinman L, et al
    Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
    J Neuroimmunol. 2017;313:77-81.
    PubMed     Abstract available


  215. TAYLOR JM
    Tissue resident macrophages are sufficient for demyelination during peripheral nerve myelin induced experimental autoimmune neuritis?
    J Neuroimmunol. 2017;313:69-76.
    PubMed     Abstract available


  216. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Abstract available


  217. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Abstract available


  218. LIU J, Lian Z, Chen H, Shi Z, et al
    Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: A systematic review and meta-analysis.
    J Neuroimmunol. 2017;313:25-33.
    PubMed     Abstract available


  219. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Abstract available


  220. GLENN JD, Xue P, Whartenby KA
    Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Dec 8. pii: S0165-5728(17)30303.
    PubMed     Abstract available


  221. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Abstract available


    November 2017
  222. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Abstract available


  223. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Abstract available


  224. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Corrigendum to Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders" [J. Neuroimmunol. 310. (2017) 150-157].
    J Neuroimmunol. 2017;312:66.
    PubMed    


  225. WANG Y, Zhang W, Yin J, Lu Q, et al
    Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    J Neuroimmunol. 2017;312:59-65.
    PubMed     Abstract available


  226. HESSELMARK E, Bejerot S
    Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel.
    J Neuroimmunol. 2017;312:31-37.
    PubMed     Abstract available


  227. SVEINSSON O, Granqvist M, Forslin Y, Blennow K, et al
    Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
    J Neuroimmunol. 2017;312:15-18.
    PubMed     Abstract available


  228. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Abstract available


  229. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Abstract available


    October 2017
  230. LIU W, Zhu M, Yu Z, Yin D, et al
    Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Oct 31. pii: S0165-5728(17)30191.
    PubMed     Abstract available


  231. PALTERER B, Brugnolo F, Sieni E, Barilaro A, et al
    Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
    J Neuroimmunol. 2017;311:10-13.
    PubMed     Abstract available


  232. LEI HW, Wang JY, Dang QJ, Yang F, et al
    Neuropsychiatric involvement in lupus is associated with the Nogo-a/NgR1 pathway.
    J Neuroimmunol. 2017;311:22-28.
    PubMed     Abstract available


  233. HUANG ZL, Pandya D, Banta DK, Ansari MS, et al
    Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.
    J Neuroimmunol. 2017;311:40-48.
    PubMed     Abstract available


    September 2017
  234. FERNANDEZ HURST N, Zanetti SR, Baez NS, Bibolini MJ, et al
    Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Sep 30. pii: S0165-5728(17)30297.
    PubMed     Abstract available


  235. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Abstract available


  236. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.
    PubMed    


  237. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Abstract available


  238. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Abstract available


  239. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Abstract available


  240. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Abstract available


  241. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Abstract available


  242. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.
    PubMed    


  243. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Abstract available


  244. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.
    J Neuroimmunol. 2017;310:51-59.
    PubMed     Abstract available


  245. ZHU DS, Yu L, Li M, Han L, et al
    High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
    J Neuroimmunol. 2017;310:32-37.
    PubMed     Abstract available


  246. WANG J, Yang C, Zhao Q, Zhu Z, et al
    Microglia activation induced by serum of SLE patients.
    J Neuroimmunol. 2017;310:135-142.
    PubMed     Abstract available


  247. LINDSEY JW
    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Abstract available


  248. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Abstract available


  249. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Abstract available


  250. LAZARIDIS K, Dalianoudis I, Baltatzidi V, Tzartos SJ, et al
    Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2017 Sep 6. pii: S0165-5728(17)30332.
    PubMed     Abstract available


    August 2017
  251. YESHOKUMAR AK, Gordon-Lipkin E, Arenivas A, Cohen J, et al
    Neurobehavioral outcomes in autoimmune encephalitis.
    J Neuroimmunol. 2017 Aug 31. pii: S0165-5728(17)30274.
    PubMed     Abstract available


  252. ALVAREZ BRAVO G, Yusta Izquierdo A, Carvalho Monteiro G, Sanchez I, et al
    Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.
    J Neuroimmunol. 2017 Aug 19. pii: S0165-5728(17)30265.
    PubMed     Abstract available


  253. LIU RT, Zhang P, Yang CL, Pang Y, et al
    ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
    J Neuroimmunol. 2017 Aug 18. pii: S0165-5728(17)30182.
    PubMed     Abstract available


  254. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Abstract available


  255. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Abstract available


  256. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Abstract available


  257. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Abstract available


  258. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Abstract available


  259. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Abstract available


  260. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Abstract available


  261. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Abstract available


  262. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Abstract available


  263. LI X, Lin J, Pan S, Weng Y, et al
    Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;309:68-71.
    PubMed     Abstract available


  264. KON T, Ueno T, Suzuki C, Nunomura J, et al
    Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.
    J Neuroimmunol. 2017;309:38-40.
    PubMed     Abstract available


  265. LIU J, Shi Z, Lian Z, Chen H, et al
    Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population.
    J Neuroimmunol. 2017;309:23-30.
    PubMed     Abstract available


  266. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Abstract available


  267. SUCHDEV K, Razmjou S, Venkatachalam P, Khan OA, et al
    Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient.
    J Neuroimmunol. 2017;309:1-3.
    PubMed     Abstract available


  268. AHMAD SF, Ansari MA, Nadeem A, Bakheet SA, et al
    Adenosine A2A receptor signaling affects IL-21/IL-22 cytokines and GATA3/T-bet transcription factor expression in CD4+ T cells from a BTBR T+ Itpr3tf/J mouse model of autism.
    J Neuroimmunol. 2017 Aug 9. pii: S0165-5728(17)30253.
    PubMed     Abstract available


  269. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Abstract available


    July 2017
  270. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Abstract available


    June 2017
  271. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Abstract available


  272. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Abstract available


  273. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Abstract available


  274. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Abstract available


  275. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Abstract available


  276. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Abstract available


  277. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Abstract available


  278. BARROS PO, Dias ASO, Kasahara TM, Ornelas AMM, et al
    Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.
    J Neuroimmunol. 2017;307:82-90.
    PubMed     Abstract available


    May 2017
  279. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Abstract available


  280. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Abstract available


  281. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Abstract available


  282. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Abstract available


  283. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Abstract available


  284. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Abstract available


  285. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Abstract available


    April 2017
  286. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Abstract available


  287. DENG B, Liu XN, Li X, Zhang X, et al
    Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
    J Neuroimmunol. 2017;305:84-91.
    PubMed     Abstract available


  288. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.
    J Neuroimmunol. 2017;305:59-67.
    PubMed     Abstract available


  289. ZHOU L, Huang Y, Li H, Fan J, et al
    MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients.
    J Neuroimmunol. 2017;305:19-28.
    PubMed     Abstract available


  290. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Abstract available


  291. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Abstract available


  292. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Abstract available


    February 2017
  293. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Abstract available


  294. LAZARIDIS K, Baltatzidi V, Trakas N, Koutroumpi E, et al
    Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.
    J Neuroimmunol. 2017;303:13-21.
    PubMed     Abstract available


  295. WARNECKE A, Musunuri S, N'diaye M, Sandalova T, et al
    Nitration of MOG diminishes its encephalitogenicity depending on MHC haplotype.
    J Neuroimmunol. 2017;303:1-12.
    PubMed     Abstract available


    January 2017
  296. ZHANGBAO J, Zhou L, Li X, Cai T, et al
    The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    J Neuroimmunol. 2017;302:49-55.
    PubMed     Abstract available


    December 2016
  297. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Abstract available


    November 2016
  298. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: